Fraser Conrad, MS

Title(s)Project and Policy Manager, Dean's Office
SchoolSchool of Medicine
Address1001 Potrero Avenue, #5420
San Francisco CA
Phone--
ORCID ORCID Icon0000-0001-6908-8475 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCSF, San Francisco, CAMS09/2017Healthcare Administration and Interprofessional Leadership
    UCSF, San Francisco, CA08/2015School of Medicine Leadership Development Program
    University of Oklahoma, Norman, OKBS05/2001Health Sciences

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice. Toxins (Basel). 2023 04 30; 15(5). Fan Y, Lou J, Tam CC, Wen W, Conrad F, Leal da Silva Alves P, Cheng LW, Garcia-Rodriguez C, Farr-Jones S, Marks JD. PMID: 37235351; PMCID: PMC10222606.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    2. Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F. PLoS One. 2022; 17(9):e0273512. Fan Y, Sun Z, Conrad F, Wen W, Zhao L, Lou J, Zhou Y, Farr-Jones S, Marks JD. PMID: 36048906; PMCID: PMC9436041.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    3. A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D. Toxins (Basel). 2021 09 10; 13(9). Garcia-Rodriguez C, Yan S, Geren IN, Knopp KA, Dong J, Sun Z, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD. PMID: 34564645; PMCID: PMC8472335.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    4. The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA. Toxins (Basel). 2019 12 20; 12(1). Fan Y, Barash JR, Conrad F, Lou J, Tam C, Cheng LW, Arnon SS, Marks JD. PMID: 31877649; PMCID: PMC7020490.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCellsPHPublic Health
    5. A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. Toxins (Basel). 2018 03 01; 10(3). Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD. PMID: 29494481; PMCID: PMC5869393.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    6. A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Toxins (Basel). 2018 02 15; 10(2). Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD. PMID: 29462889; PMCID: PMC5848185.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    7. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS One. 2017; 12(3):e0174187. Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks JD. PMID: 28323873; PMCID: PMC5360321.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCellsPHPublic Health
    8. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. J Infect Dis. 2016 May 15; 213(10):1606-14. Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS. PMID: 26936913; PMCID: PMC4837907.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    9. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins (Basel). 2015 Aug 26; 7(9):3405-23. Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD. PMID: 26343720; PMCID: PMC4591640.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    10. Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS One. 2015; 10(8):e0135306. Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD. PMID: 26275214; PMCID: PMC4537209.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    11. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther. 2012 Jul; 11(7):1467-76. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. PMID: 22564724; PMCID: PMC4209485.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    12. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol. 2010 Apr 09; 397(4):1106-18. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. PMID: 20138889; PMCID: PMC2903050.
      View in: PubMed   Mentions: 47     Fields:    Translation:AnimalsCells
    13. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl). 2009 May; 87(5):507-14. Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B. PMID: 19219419; PMCID: PMC2796542.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    14. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther. 2007 Oct; 6(10):2737-46. Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B. PMID: 17938267.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    15. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med (Berl). 2007 Oct; 85(10):1113-23. Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. PMID: 17554518.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    16. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):704-10. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. PMID: 14744788.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Fraser's Networks
    Concepts (97)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (7)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.